Both PROTAC compounds have demonstrated induction of apoptosis in Tregs and the activation of tumor infiltrating CD8+ T cells resulting in a decrease in tumor growth in immunocompetent tumor models; this suggests that targeting of BCL-XL may also have the potential to improve cancer immunotherapy [50]. Here, BCL2L1 is linked to cancer.